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Abstract
The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K) pathway is fundamental for cancer cell proliferation and
is known to be frequently altered and activated in neoplasia, including embryonal tumors. Based on the high frequency of
alterations, targeting components of the PI3K signaling pathway is considered to be a promising therapeutic approach for
cancer treatment. Here, we have investigated the potential of targeting the axis of the insulin-like growth factor-1 receptor
(IGF-1R) and PI3K signaling in two common cancers of childhood: neuroblastoma, the most common extracranial tumor in
children and medulloblastoma, the most frequent malignant childhood brain tumor. By treating neuroblastoma and
medulloblastoma cells with R1507, a specific humanized monoclonal antibody against the IGF-1R, we could observe cell
line-specific responses and in some cases a strong decrease in cell proliferation. In contrast, targeting the PI3K p110a with
the specific inhibitor PIK75 resulted in broad anti-proliferative effects in a panel of neuro- and medulloblastoma cell lines.
Additionally, sensitization to commonly used chemotherapeutic agents occurred in neuroblastoma cells upon treatment
with R1507 or PIK75. Furthermore, by studying the expression and phosphorylation state of IGF-1R/PI3K downstream
signaling targets we found down-regulated signaling pathway activation. In addition, apoptosis occurred in embryonal
tumor cells after treatment with PIK75 or R1507. Together, our studies demonstrate the potential of targeting the IGF-1R/
PI3K signaling axis in embryonal tumors. Hopefully, this knowledge will contribute to the development of urgently required
new targeted therapies for embryonal tumors.
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Introduction
Second to accidents, cancer is still the leading cause of death for
children. Embryonal tumors represent approximately 30% of
childhood malignancies and often display resistance to current
therapeutic regimens. Therefore, embryonal tumors are associated
with lower survival rates compared to other childhood cancers.
Treatment failure for disseminated disease is frequent, and results
in survival rates ,20%. Thus, novel therapeutic options are
urgently needed for this group of tumors to improve survival rates
and quality of life of patients. Embryonal tumors are dysontoge-
netic tumors whose pathological features resemble those of the
developing organ or tissue of origin and include the entities
medulloblastoma and neuroblastoma. Medulloblastoma is the
most common malignant brain tumor in children and accounts for
approximately 20% to 25% of all pediatric central nervous system
tumors. Neuroblastoma is an embryonal tumor that originates
from developing neural crest tissues. It is the most common
extracranial solid tumor and is responsible for 15% of all cancer-
related deaths in childhood. The fact that these cancers occur in
infants and young children suggests that only a limited number of
genetic changes may lead to tumor development, making these
cancers an attractive model to identify new molecular targets. The
development of novel targeted therapies is of particular impor-
tance for embryonal tumors, as these malignancies are orphan
diseases. Common intracellular signaling pathways and chromo-
somal deletions including 1p36 and 11q loss have been previously
identified in different embryonal tumors, including medulloblas-
toma and neuroblastoma [1–10].
Several intracellular signaling pathways have indeed been
demonstrated to play a key role in embryonal tumor biology.
Indeed, polypeptide growth factors such as insulin-like growth
factor-1 (IGF-1), epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), neuregulins and neurotrophins have been
shown to control embryonal tumor proliferation, survival,
differentiation and metastasis [11–15] by binding to specific
receptor tyrosine kinases (RTKs). Moreover, expression of the
ErbB-2 and ErbB-4 RTKs in embryonal tumor samples was
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shown to correlate with reduced patient survival, while Trk
receptor expression correlated with a less aggressive tumor
phenotype [13]. Therefore a better understanding of the
involvement of RTKs and their downstream targets in human
embryonal tumor biology may yield important clues for the
development of new drugs for the disease. Targeting receptor
tyrosine kinases such as the IGF-1R is a promising approach to
develop novel anti-cancer therapies in embryonal tumors, such as
neuroblastoma and sarcoma [15–23]. Indeed the first results from
clinical trials evaluating the safety and efficacy of IGF-1R
neutralizing antibodies in children and adolescents with embry-
onal tumors have been reported [24,25]. In these trials, the
humanized IGF-1R neutralizing antibody R1507 displayed
minimal toxicities and some responses in ESFT were observed
[24,25]. Importantly, no dose-limiting toxicities were identified
and the maximum tolerated dose was not reached [24]. Human
embryonal tumor cells have been reported to express a variety of
growth factor receptors, some of which can be activated by
mutations, over-expression and/or establishment of autocrine
loops [13]. Amongst these polypeptide growth factor receptors are
the RTKs IGF-1R, EGFR, ALK, ErbB-2, ErbB-4, c-Kit,
PDGFR, Trk and fibroblast growth factor receptor (FGFR) [26–
41]. Therefore, given that embryonal tumor cells express a variety
of different growth factor receptors, targeting individual receptors
may not provide a successful therapeutic strategy in all embryonal
tumor entities. A potentially complementary approach would be to
identify signaling molecules which lie downstream of several
different growth factor receptors and which are essential for
transmitting their proliferative and/or survival message. Combi-
natorial targeting of receptor tyrosine kinases (such as the IGF-1R)
and their downstream signaling mediators is a very promising
approach to develop more efficient anti-cancer therapies
[16,17,22,42–44].
The phosphoinositide 3-kinase (PI3K) plays a crucial role in
controlling cell proliferation, survival and motility/metastasis
downstream of many different growth factor receptors and
oncogenic Ras mutants [45–48]. PI3K signaling activates a crucial
intracellular signaling pathway involving phosphoinositide-depen-
dent protein kinase-1 (PDK1), Akt, the mammalian target of
rapamycin (mTOR) and the ribosomal protein S6 kinase (S6K),
which controls cell growth, proliferation and survival [45–47]. The
importance of PI3K/Akt/mTOR signaling in cancer is highlight-
ed by the fact that mutations in the tumor suppressor gene PTEN
occur frequently in human tumors, including glioblastoma [45,49–
51]. PTEN is a phosphatase that antagonizes the action of PI3K
by de-phosphorylating the D-3 position of poly-phosphoinositides
[45,49,50]. Reduced expression of PTEN resulting in activation of
PI3K signaling was recently described in embryonal tumors such
as medulloblastoma and neuroblastoma [52,53]. Moreover,
various reports have described activating mutations in the PIK3CA
gene encoding the catalytic p110a isoform of PI3K in a variety of
human cancers, including, breast, colon and ovarian cancer, as
well as embryonal tumors [51,54,55]. In addition, PI3K/Akt/
mTOR signaling has been demonstrated to mediate the prolifer-
ation of embryonal tumor cells [56,57] and to contribute to
signaling by ErbB-2 and IGF-1R [58–60]. Activation of Akt was
Figure 1. The effect of R1507 on cell proliferation of NB and MB cells. A panel of NB cell lines (A) and MB cell lines (B) were incubated with
increasing concentrations of the antibody R1507 inhibiting the IGF-1R in serum-containing medium. Cell viability was assessed using the MTS assay
after 2 days. The data represent the mean with SD from at least 6 replicates and 3 independent experiments.
doi:10.1371/journal.pone.0047109.g001
IGF-1R Targeting in Embryonal Tumors
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also reported in embryonal tumors, correlating with poor outcome
in some entities [61]. Thus, targeting the PI3K/Akt/mTOR
signaling pathway may represent an attractive novel approach to
develop novel therapies for embryonal tumors [62]. Indeed, there
now exist multiple pharmacological inhibitors of the PI3K/Akt/
mTOR pathway which have entered clinical trials for adult and
pediatric cancer [44,46,48,63–65]. The PI3K/Akt/mTOR path-
way is also an important contributor to the resistance of human
tumors to drugs targeting receptor tyrosine kinases [66–68].
Inhibitors of the PI3K/Akt/mTOR signaling pathway have also
been shown to be effective in combination with IGF-1R inhibitors
[20,43].
In the present report, we have evaluated the anti-proliferative
potential of the humanized anti-IGF-1R antibody R1507 and of
PIK75, a class IA PI3K inhibitor, in medulloblastoma and
neuroblastoma cell lines. We present evidence that these agents
are effective as monotherapies in subsets of embryonal tumor cell
lines and can be effectively combined with standard chemother-
apeutic drugs.
Materials and Methods
Antibodies and reagents
Antibodies specific for IGF1Rb, PI3K p110a, Akt1/2/3, ERK
1/2, S6 protein, Caspase-3 (Santa Cruz Biotechnology, CA, USA),
Figure 2. Sensitivity to R1507 and PIK75, and presence of IGFR in neuroblastoma cell lines LAN1 and LAN1R, a LAN1 cell line
resistant to doxorubicin. (A) R1507 treatment for 48 hours. (B) PIK75 treatment for 48 hours. Error bars represent 6S.D. of means from 3
experiments, each with 3 replicates, except that there was only one experiment with 500 nM PIK75 in B. (C) Western blot analysis of components of
the IGF-1R/PI3K pathway in LAN1 and LAN1R whole cell extracts. Src was used as internal loading control. (D) Transfection of LAN1 cells with siRNA
targeting the IGF-1R (non-targeting siRNA was used as control. Expression levels of the IGF-1R were assessed by Western blot analysis in LAN1 whole
cell lysates after 96 h). Cell proliferation in LAN1 cells upon IGF-1R silencing was assessed in absence or presence of R1507 after 96h by MTS.
(*p,0.05).
doi:10.1371/journal.pone.0047109.g002
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phospho-ERK1/2 (Thr202/Tyr204), phospho-Akt (Ser473; Thr308),
poly (ADP-ribose) polymerase (PARP), S6 protein, phospho-S6
(Ser235/Ser236; Ser240/Ser244) p-IGF-1R(Cell Signaling Technol-
ogy), b-actin (Sigma Aldrich).
The PI3K inhibitor PIK-75 [69] was dissolved in DMSO
(Sigma, Buchs, Switzerland) at 10 mM and diluted into cell culture
medium just before use. R1507, a fully human IgG1 monoclonal
antibody to IGF-1R, was obtained from Roche, and was diluted
directly into the medium immediately before use. The chemo-
therapeutic agents cisplatin (Bristol-Myers Squibb), doxorubicin
(Pfizer) and etoposide (Calbiochem) were used in combination
with PIK75 or R1507 at the indicated concentrations.
Cell lines, cell culture, cell proliferation and apoptosis
Human neuroblastoma cells were from the American Type
Culture Collection and were kindly provided by Dr. Brodeur,
Children’s Hospital of Philadelphia. The cells were grown in
RPMI (Life Technologies/Invitrogen) supplemented with 10% (v/
v) fetal calf serum (FCS) and penicillin/streptomycin/L-glutamine
and passaged every 3–5 days by trypsinization [20,70].
The medulloblastoma cell lines’ provenience has been previ-
ously described. DAOY, UW-228 and PFSK human cell lines
were purchased from the American Type Culture Collection.
D341 Med and D458 Med medulloblastoma cells were the kind
gift of Dr. Henry Friedman (Duke University, Durham, NC)
[71,72]. Cell lines that were not purchased from the American
Type Culture Collection in 2009 were tested for their authenti-
cation by karyotypic analysis using molecular cytogenetic
techniques, such as comparative genomic hybridization. DAOY
medulloblastoma cell line was grown in Richter’s MEM Zinc
option medium (Invitrogen) with 10% FCS (fetal bovine serum;
Sigma) and penicillin/streptomycin (Invitrogen). PFSK primitive
neuroectodermal tumor (PNET) cell line [73] was grown in RPMI
1640 (Invitrogen) with 10% FCS and penicillin/streptomycin/L-
glutamine. The UW-228 medulloblastoma cell line was grown in
DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen) with
10% FCS and penicillin/streptomycin/L-glutamine. D341 Med
and D458 Med medulloblastoma cell lines were grown like DAOY
but with the addition of 100M non-essential amino acids
(GIPCOTM MEM Invitrogen). All cells were grown in a
humidified atmosphere at 37u and 5% CO2 [74,75].
For cell viability assays neuroblastoma and medulloblastoma
cells were seeded in 96-well plates at a density of 39000–109000
cells/well and grown for 48–118 hrs in cell culture containing high
(10%) serum. Cell proliferation was analyzed by the CellTiter
96HAQueousOne Solution Cell Proliferation Assay (Promega)
according to the manufacturer’s instructions. For detection of
apoptosis, NB and MB cells were seeded on 6-well plates and
incubated for 24 h in the presence or absence of PIK75, R1507 or
cisplatin. After lysis of the cells the protein samples were analyzed
by SDS-PAGE and Western blot with anti-PARP and anti-
caspase-3 antibodies. Additionally, apoptosis was analyzed by
caspase 3/7 activation using the Caspase-Glo 3/7 Assay
(Promega), according to the manufacturer’s instruction.
Figure 3. Cell proliferation of NB and MB cells after inhibition of the PI3K p110a. A panel of NB cell lines (A) and MB cell lines (B) were
incubated with increasing concentrations of the specific pharmacological PI3K p110a inhibitor PIK75 in serum-containing medium. Cell viability was
assessed using the MTS assay after 2 (NB) or 3 (MB) days. The data represent the mean with SD from at least four replicates and 1–3 independent
experiment.
doi:10.1371/journal.pone.0047109.g003
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Western blotting
Cell lysates were prepared in RIPA buffer (50 mM Tris-Cl,
pH 6.8, 100 mM NaCl, 1% Triton X-100, 0.1% SDS) supple-
mented with Complete Mini Protease Inhibitor Cocktail (Roche
Applied Sciences) and with the phosphatase inhibitors b-glycero-
phosphate (20 mM) and Na3VO4 (200 mM) and normalized using
a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL,
USA). Cell lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a
hydrophobic polyvinylidenedifluoride (PVDF) membrane (Hy-
bond-P; Amersham Biosciences, GE Healthcare, UK) and
immunoblotted with the indicated antibodies prior to chemilumi-
nescent detection (SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA).
siRNA transfection
LAN-1 neuroblastoma cells (104 cells per well) were plated in
96-well plates and transfected 24 h later with siRNA targeting the
IGF-1R or non-targeting siRNA (Ambion, Applied Biosystems,
Foster City, CA, USA) at a final concentration of 30 nM, using
Lipofectamine 2000 following the manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA). Twenty-four hours following
transfection, cells were treated with R1507 (at different concen-
trations). Cell viability was analyzed after 72 h.
Figure 4. PI3K and IGF-1R inhibition impair receptor activation and downstream signaling. The NB cells SH-SY5Y (A), LAN1 (B); WAC2 (C)
and the MB cells PFSK (D) grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110a inhibitor PIK75 and
the IGF-1R antibody R1507. After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and Western blotting for the
proteins indicated. Serum-starved DAOY (E) or LAN1 (F) cells were pre-treated with vehicle or R1507 at the concentrations indicated for 1h and
stimulated with IGF-1 (50 ng/ml or 100 ng/ml) for 10 min at 37uC. Cell lysates were analysed by SDS-PAGE and Western Blot for phosphorylated IGF-
1R beta and total receptor.
doi:10.1371/journal.pone.0047109.g004
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Statistical analysis
Analysis of variance was used to assess statistical significance of
differences between groups. p values ,0.05 were considered as
significant.
Results
Anti-proliferative activity of R1507 and PIK75 in panels of
neuroblastoma and medulloblastoma cell lines
We have previously described panels of neuroblastoma and
medulloblastoma cell lines, which were characterized for expres-
sion of components of the IGF-1R/PI3K signaling pathway
[20,70,75]. In the present study, the impact of the humanized anti-
IGF-1R antibody R1507 was evaluated on cell proliferation in vitro
in the panels of neuroblastoma and medulloblastoma cell lines
(Fig. 1). The antibody displayed anti-proliferative activity in 2 out
of 8 neuroblastoma cell lines, namely SH-SY5Y and LAN1
(Fig. 1A and 2A). In SH-SY5Y, R1507 induced a maximal
decrease in cell viability of 60% at 12.5 mg/ml (Fig. 1A). In LAN1
a maximal activity of ,25% reduction in cell proliferation was
observed (Fig. 2A). R1507 showed anti-proliferative activity in 2
out of 5 medulloblastoma cell lines, namely PFSK and D458
(Fig. 1B). In D458, a maximal decrease in cell proliferation (60%)
was observed at 15 mg/ml, while in PFSK the maximal effect was
40% inhibition of the response (Fig. 1B). In NB and MB cell lines,
the activity of R1507 was cell-line specific and the antibody had a
profile similar to the IGF-1R tyrosine kinase inhibitor NVP-
AEW541 [20]. NVP-AEW541 was more active in SH-SY5Y and
LAN-1 than in other neuroblastoma cell lines [20], and PFSK
were more sensitive to NVP-AEW541 than DAOY and UW228
cells. The expression levels of the IGF-1R in NB cells did not
correlate with the activity of R1507, as previously observed with
NVP-AEW541 [20]. Similarly, in the MB cell line panel which
was previously analyzed for IGF-1R expression [75], there was
apparently no correlation between receptor expression and the
activity of R1507.
The impact of the class IA PI3K inhibitor PIK75 was evaluated
on cell proliferation in vitro in the panels of neuroblastoma and
medulloblastoma cell lines (Fig. 3). The inhibitor displayed strong
anti-proliferative activity in the neuroblastoma cell line panel, with
IC50 values in the range of 50–100 nM (Fig. 3A). In medulloblas-
toma cell lines, PIK75 was more active in D341 and D458 cells
(IC50 = 20 nM) than in UW228 cells. The activity of PIK75 in
DAOY and PFSK cells was previously described [75].
Impact of R1507 and PIK75 on intracellular signaling
pathway activation
The impact of R1507 and PIK75 on the activation status of the
Akt/mTOR pathway in NB cell lines was investigated by Western
blot analysis (Fig. 4). R1507 strongly affected the activation status
of Akt and the phosphorylation of the mTOR downstream target
ribosomal S6 protein in the R1507-responsive NB and MB cell
lines. (SH-SY5Y in Fig. 4A, LAN1 cells Fig. 4B, as well as in
medulloblastoma PFSK cells Fig. 4D). Concentrations of 6.25–
100 mg/ml R1507 reduced AktSer473 phosphorylation, whereas
only concentrations of more than 6.25 or 12.5 were needed to
reduce S6Ser235/236 phosphorylation. In the R1507-insensitive NB
cell line WAC2, the antibody did not induce a comparable
response in terms of inhibition of the PI3K signaling pathway
(Fig. 4C).
Also PIK75 was able to inhibit Akt/mTOR activation, as seen
on the decreases in the phosphorylation of S6 protein in both NB
cell lines treated (Fig. 4A+B), although only in LAN-1 cells the
phosphorylation of AktSer473 was affected (Fig. 4B). The inhibitory
effects of PIK75 in Akt/mTOR signaling in MB cell lines cells
were previously described in [75] and correlate with the effects
observed in neuroblastoma cells.
Figure 5. Treatment of NB cells with R1507 or PIK75 in presence of chemotherapy results in additive effects. NB cells grown in serum-
containing medium were incubated with the IGF-1R antibody R1507 (0.1 mg/ml) (A) or the PI3K inhibitor PIK75 (0.05 mM) (B+C) in presence or
absence of cisplatin (1 mM), etoposide (1 mM), or doxorubicin (0.1 mM). Cell proliferation was assessed using the MTS assay after 48 h. The data
represent the mean of 8 replicates with SD from 3 independent experiments. (*p,0.05).
doi:10.1371/journal.pone.0047109.g005
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IGF-1R expression and activation in neuroblastoma and
medulloblastoma cell lines
Further, we wanted to investigate the impact of R1507 on the
expression and activation status on the IGF-1 receptor in MB and
NB cell lines. Pre-treatment with R1507 inhibited the phosphor-
ylation but not the expression level of IGF-1R in DAOY and
LAN1 cells after IGF-1 stimulation (Fig. 4E+F).
Combination of R1507 with standard chemotherapeutic
agents in neuroblastoma and medulloblastoma cell lines
We have previously shown that the IGF-1R tyrosine kinase
inhibitor NVP-AEW541 enhances the effects of cisplatin on cell
proliferation and apoptosis in neuroblastoma cell lines [20]. In
support of this finding, the concomitant treatment of the R1507-
responsive SH-SY5Y neuroblastoma cell line with R1507 and
cisplatin resulted in additive effects on cell proliferation (Fig. 5A).
For neuroblastoma WAC2 cells that did not respond to R1507 in
single treatment (Fig. 1A), there was no additional effect of R1507
in combination with cisplatin, doxorubicin or etoposide (Fig. S1).
In medulloblastoma PFSK and UW228 cells, the combination of
R1507 and cisplatin was more effective than the single agents
(Fig. 6A+B). This is not surprising for PFSK, that also showed
sensitivity to R1507 alone, but in UW228, cisplatin seems to
Figure 6. Additive/sensitization effects after combinatorial treatment with R1507 and chemotherapy in MB cells. The MB cell lines
PFSK (A), UW228 (B) and DAOY (C) grown in serum-containing medium were incubated with increasing concentrations of cisplatin in presence or
absence of the IGF-1R antibody R1507 (25 mg/ml or 50 mg/ml). Cell proliferation was assessed using the MTS assay after 48 h. The data represent the
mean of 6 replicates with SD from 3 independent experiments.
doi:10.1371/journal.pone.0047109.g006
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confer R1507 sensibility. In R1507-insensitive DAOY cells no
such effect was observed (Fig. 6C).
Combination of PIK75 with standard chemotherapeutic
agents in neuroblastoma cells
In the neuroblastoma cell lines LAN1 and WAC2, the
concomitant treatment with PIK75 and doxorubicin or etoposide
resulted in additive effects on cell proliferation (Fig. 5B+C). At
selected, relatively low concentrations, where PIK75, doxorubicin
or etoposide alone reduced cell proliferation to 60–80%,
combination treatments of PIK75 and one of the chemothera-
peutic agents brought reductions to 40–50%. Our previous work
on medulloblastoma has shown that PIK75 sensitizes medullo-
blastoma cell lines to doxorubicin [75].
Inhibitors of the RTK-PI3K-mTOR signaling in
medulloblastoma
Beside classical chemotherapeutic agents used for cancer
treatment, targeted therapies involving inhibitors of the RTK-
PI3K signaling axis are considered to be a promising approach in
cancer treatment. To investigate the role of receptor tyrosine
kinases signaling in medulloblastoma, the effect of different
targeted therapies was additionally studied. In vitro, the IGF-1R
inhibitor NVP-AEW541 reduced the cell viability of the MB cell
line DAOY with an IC50 of 2.5 mM and a maximal reduction of
cell proliferation to 5% (Fig. 7A, 8C), whereas in UW228 cells
concentrations higher than 10 mM were needed to provoke a
response (Fig. 7B). Also targeting the EGFR with gefinitib or
erlotinib was more effective in DAOY than in UW228 cells
(Fig. 7A+B), with DAOY responding from concentrations higher
than 2.5 mM. In UW228 cells erlotinib did not cause any effect,
whereas gefitinib treatment reduced cell viability to 5% at the
highest concentration tested (20 mM) (Fig. 7B). Rapamycin, a
commonly used mTOR inhibitor, led to 50% reduction in cell
proliferation in DAOY cells (0.0625 mg/ml) (Fig. 8D). UW228
cells responded to rapamycin with a maximum decrease in cell
viability of 30% (2 mg/ml) (Fig. 7B). Imatinib, an inhibitor of the
RTKs PDGFR and c-Kit, was able to reduce the cell proliferation
in DAOY cells to 15% (Fig. 7A, 8B) and in UW228 cells to 40%
(Fig. 7B). Before, it could be shown that the concomitant treatment
of the IGF-1R antibody R1507 with cisplatin resulted in additive
effects in R1507-responsive cell lines, or even was able to sensitize
the R1507-non-responsive cell line UW228, but not DAOY
(Fig. 6). Furthermore it was of interest, whether a concomitant
treatment of different RTK/PI3K/mTOR inhibitors and R1507
could cause sensitization effects in non-responsive DAOY cells.
Figure 7. Apoptosis upon PI3K inhibition. (A+B) The NB cell lines LAN1 (A, left panel; B, left panel) and SH-SY5Y (B, right panel) as well as the MB
cell line PFSK (A, right panel) grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110a inhibitor PIK75
and the IGF-1R antibody R1507, or cisplatin. After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and Western
blotting for the proteins indicated. (C) The NB cell line WAC2 grown in serum-containing medium was incubated with increasing concentrations of
the PI3K p110a inhibitor PIK75. Caspase 3/7 activity was assessed using the Caspase 3/7 Glo assay after 48 h.
doi:10.1371/journal.pone.0047109.g007
IGF-1R Targeting in Embryonal Tumors
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e47109
Co-targeting EGFR (gefitinib) or PDGFR and c-Kit (imatinib)
together with the IGF-1R (R1507) was not able to sensitize DAOY
cells, and interestingly, even caused negative effects, meaning the
combination treatment was less effective than the single agent
(Fig. 8A+B). R1507, in combination with the IGF-1R inhibitor
Figure 8. Targeted therapies in medulloblastoma. The MB cell lines Daoy (A) and UW228 (B) were incubated with increasing concentrations of
the EGFR inhibitors gefinitib or erlotinib, the Abl inhibitor imatinib, the IGF-1R inhibitor NVP-AEW541 and the mTOR inhibitor rapamycin. Cell
proliferation was assessed using the MTS assay after 72 h. The data represent the mean of 6 replicates with SD from 3 independent experiments.
doi:10.1371/journal.pone.0047109.g008
IGF-1R Targeting in Embryonal Tumors
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NVP-AEW541 or the mTOR inhibitor rapamycin could not
further increase the effect of the single treatment (Fig. 8C+D).
The role of the IGF-1R/PI3K/Akt signaling axis on cell
survival in neuroblastoma and medulloblastoma
The impact of the IGF-1R/PI3K/Akt signaling axis on survival
of NB and MB cells was investigated by treating the cells with
increasing concentrations of R1507 or PIK75, and apoptosis was
measured by PARP cleavage and caspase-3activation, both
markers of apoptotic activity. Whereas PIK75 treatment led to
enhanced PARP and pro-caspase 3 cleavage in LAN1 and SH-
SY5Y cells (Fig. 9A+B) or to an increase in the caspase 3/7 activity
in WAC2 NB cells (Fig. 9C), a comparable induction of apoptosis
could not be observed with R1507 treatment in NB cells or by
treating the MB cell line PFSK (Fig. 9A+B).
Figure 9. Effects of R1507 in combination with targeted therapies in medulloblastoma. The R1507-insensitive cell line DAOY was
incubated with increasing concentrations of the EGFR inhibitor gefinitib (A), the Abl inhibitor imatinib (B), the IGF-1R inhibitor NVP-AEW541 (C) and
the mTOR inhibitor rapamycin (D) in presence or absence of the IGF-1R antibody R1507. Cell proliferation was assessed using the MTS assay after
72 h. The data represent the mean of 6 replicates with SD from 3 independent experiments.
doi:10.1371/journal.pone.0047109.g009
IGF-1R Targeting in Embryonal Tumors
PLOS ONE | www.plosone.org 10 October 2012 | Volume 7 | Issue 10 | e47109
Activity of R1507 and PIK75 in chemoresistant NB cell
lines
We next investigated whether R1507 or PIK75 had also anti-
proliferative effects in neuroblastoma cell lines with acquired
resistance to standard chemotherapeutic agents (LAN1R). R1507
displayed no significant anti-proliferative activity in LAN1 cells
with acquired resistance to doxorubicin (Fig. 2A). In contrast,
PIK75 displayed almost comparable anti-proliferative activity in
either parental LAN1 or their chemoresistant counterparts
(Fig. 2B). Western blot analysis of the protein expression of
LAN1R cells showed that these cells express reduced levels of IGF-
1R and p110a compared to the parental cell line LAN1. In
addition, the phosphorylation levels of ERK1/2 and AKT at the
positions Ser473 and Thr308 were also lower in LAN1R than in
LAN1 (FIG. 2C). In order to investigate whether down-regulation
of the IGF-1R could reduce the sensitivity of NB cells to R1507,
observation, LAN1 cells were transiently transfected with siRNA
targeting the receptor. At 96 h after transfection, a 50% reduction
of IGF-1R expression was still observed (Fig. 2D). LAN1 cells
transfected with IGF-1R siRNA displayed reduced proliferation,
when compared to control cells transfected with non-targeting
siRNA (Fig. 2D). In addition, IGF-1R silencing completely
abrogated the response to R1507 (Fig. 2D), confirming that
down-regulation of the receptor in the LAN1R cells contributes to
the lack of effect of R1507 in these cells (Fig. 2A).
Discussion
In the present report we have evaluated the anti-proliferative
activity of the humanized anti-IGF-1R antibody R1507 in the
embryonal tumors neuroblastoma and medulloblastoma in vitro. As
a single agent, R1507 was effective in a subset of neuro- and
medulloblastoma cell lines, while a majority of cell lines did not
respond. The profile of R1507 in neuro- and medulloblastoma was
similar to the IGF-1R tyrosine kinase inhibitor NVP-AEW541 in
terms of the identity of the cell lines which were sensitive to the
single agent [20]. The expression levels of the IGF-1R in MB and
NB cells did not correlate with the activity of R1507, as previously
observed with NVP-AEW541 [20]. The constitutive activation of
downstream signaling pathways such as Akt and mTOR/S6K
may modulate the sensitivity of the cells to R1507, as previously
reported for NVP-AEW541 [20]. In neuroblastoma cell lines that
were sensitive to R1507 as single agent, the effects of R1507 and
chemotherapy (cisplatin, doxorubicin and etoposide) were addi-
tive, a result which was also observed with NVP-AEW541 [20].
However, neuroblastoma cells which were not sensitive to R1507,
showed also no additive effects in cell growth inhibition to when
combined with chemotherapies. By contrast, in medulloblastoma
R1507 showed strong additive effects with cisplatin not only in MB
cells which were initially sensitive to R1570 (PFSK), but also MB
cells which were insensitive to R1507 as a single agent (UW228).
Analysis of the mechanisms of action revealed that R1507 inhibits
cell growth by attenuation of the AKT/mTOR signaling pathway
in neuroblastoma and medulloblastoma cells. Similar observations
were obtained by inhibition of IGF-1R with NVP-AEW541 [20].
Interestingly, the concomitant treatment with R1507 and inhib-
itors of the RTK/PI3K/mTOR signaling could not overcome the
resistance of insensitive DAOY cells, resulted in combination with
gefitinib and imatinib even in negative effects, compared to when
they were used as single agent. Generally, DAOY cells responded
to single treatments targeting the RTK/PI3K/mTOR signaling,
such as IGF-1R (NVP-AEW541), EGFR (gefinitib, erlotinib),
PDGFR and c-Kit (imatinib), and mTOR (rapamycin). Cell
growth of the cell line UW228 was mostly not affected or higher
concentrations were needed to induce a response by use of the
same agents.
Our previous work using RNAi targeting of classIA PI3K
isoforms has revealed that targeting these enzymes in neuroblas-
toma and medulloblastoma cell lines can induce apoptosis and
decrease cell proliferation [70,75]. These results are supported by
the findings presented here, which show that PIK75 displays a
broad anti-proliferative activity in neuroblastoma cell lines. Also in
medulloblastoma, we observed that PIK75 has anti-proliferative
activity, but one cell line (UW228) was rather resistant to the drug.
The exact mechanism(s) underlying this observation are at present
unclear, but may be caused by an enhanced activation of Erk1/2.
A decrease in activity of class IA PI3K inhibitors has been observed
previously in cell lines with mutant KRAS and attributed to the
enhanced activation of the Erk pathway [76]. The combination of
PIK75 with chemotherapy (doxorubicin and etoposide) showed
enhanced cell growth inhibition as compared with single agent
treatment in neuroblastoma cell lines. Consistent with these
findings, a recent report demonstrated that PI103 a dual inhibitor
against p110a and mTOR strongly synergizes with various
chemotherapeutics including doxorubicin, etoposide and cisplatin
[77]. In medulloblastoma, our previous work has also demon-
strated the anti-proliferative effects for PIK75 in combination with
different chemotherapeutic agents [75].
Because neuroblastoma and medulloblastoma cells may express
a variety of different growth factor receptors, we and others have
postulated that targeting individual receptors may not always
provide the best therapeutic option [20,70,75]. To overcome this
problem, an alternative approach was proposed, which is based on
targeting downstream signaling molecules that are regulated by
different growth factor receptors to transmit the proliferative
message. Our findings support this approach, since we observed
that generally a bigger number of NB and MB cell lines most likely
responded to PIK75 than to R1507. Importantly, PIK75
effectively inhibited proliferation in a chemoresistant neuroblasto-
ma cell line in a comparable manner as in the parental cell line,
demonstrating its broad anti-proliferative activity. By contrast,
R1507 was ineffective in the chemoresistant neuroblastoma cells,
which was most likely caused by reduced expression of the IGF-
1R. The activation status of the AKT/mTOR pathway was also
found to be reduced in the chemoresistant cells, pointing that this
signaling pathway may not be responsible for the acquired
chemoresistant phenotype of the cells. However, our previous
findings in medulloblastoma cells showed elevated levels of
phosphorylated Akt as a consequence of short time exposure with
doxorubicin [75]. The molecular mechanisms underlying these
observations are at present unclear, but may be of importance, in
view of the fact that some clinical trials have been initiated with
R1507 in patients previously treated with chemotherapy [78].
Supporting Information
Figure S1 The NB cell line WAC2 is resistant to the
combinatorial treatment of R1507 with chemotherapeu-
tic agents. Neuroblastoma WAC2 cells treated with R1507 in
combination with chemotherapy, incubated for 48 hours. Already
shown to be insensitive to R1507 alone (Fig. 1A), WAC2 cells are
here shown also to be insensitive to R1507 in combination with
chemotherapeutic agents (A) doxorubicin and (B) cisplatin. Error
bars represent 6S.D. of means from 1 to 2 experiments, each with
8 replicates. For combination experiments with R1507-sensitive
neuroblastoma cell lines, see Fig. 5.
(TIF)
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